Autoimmune Gastrointestinal Dysmotility Market Growth Accelerates: Strategic Forecast Predicts $2.37 Billion by 2029

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Will the Autoimmune Gastrointestinal Dysmotility Industry Market Size Be by 2025?
The market for autoimmune gastrointestinal dysmotility has seen consistent expansion in the past few years. The growth is expected to continue from $1.73 billion in 2024 to $1.82 billion in 2025, with a compound annual growth rate (CAGR) of 5.0%. The growth observed in the past can be credited to a rising ignorance of rare diseases, an increase in underdeveloped diagnostic methods, an uptick in misdiagnoses with other gastrointestinal disorders, an escalating absence of targeted therapies, and growing delays in research advancements.

What's the Long-Term Growth Forecast for the Autoimmune Gastrointestinal Dysmotility Market Size Through 2029?
The market for autoimmune gastrointestinal dysmotility is projected to experience robust expansion in the coming years. The market is set to increase to "$2.37 billion by 2029, with a compound annual growth rate (CAGR) of 6.9%. This anticipated growth during the forecast period can be linked to the increasing instances of autoimmune diseases, the enhancement of diagnostic procedures, expansion of healthcare spending, growth of rare disease registries, and superior educational opportunities for clinicians. Key trends expected during this period encompass technological progress in diagnostic procedures, breakthroughs in immunotherapy, progress in neurogastroenterology research, exploration and advancement in motility modulators, and the adoption of individualized treatment methodologies.

View the full report here:
https://www.thebusinessresearchcompany.com/report/autoimmune-gastrointestinal-dysmotility-global-market-report

What Are the Key Growth Drivers Fueling the Autoimmune Gastrointestinal Dysmotility Market Expansion?
The autoimmune gastrointestinal dysmotility market is poised for growth due to the increasing incidence of autoimmune disorders. These maladies are characterized by the body's immune system erroneously attacking its own healthy cells, tissues, or organs rather than defending them from infections and foreign substances. The increasing frequency of these disorders is mainly attributed to a blend of genetic predisposition and environmental influences, which interfere with immune system regulation, raising the chances of the body targeting its own tissues. Autoimmune gastrointestinal dysmotility plays a key role in recognizing and managing fundamental autoimmune disorders by highlighting immune-mediated harm to the enteric nervous system, thereby relating gastrointestinal symptoms to systemic autoimmune activity. For instance, a study by Versorgungsatlas.de, a German organization, in November 2024 revealed that about 6,304,340 out of 73,241,305 surveyed in 2022 were identified with at least one autoimmune disease, culminating in a crude prevalence rate of 8.61. Hence, the surging incidence of autoimmune disorders is fueling the autoimmune gastrointestinal dysmotility market's expansion.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24160&type=smp

What Long-Term Trends Will Define the Future of the Autoimmune Gastrointestinal Dysmotility Market?
Leading businesses in the autoimmune gastrointestinal dysmotility market are adopting the approach of strategic partnerships to offer digital therapy solutions for handling the conditions related to autoimmune gastrointestinal dysmotility. Such alliances help in the improvement of care for autoimmune gastrointestinal dysmotility by providing an integrated platform for virtual healthcare with the assistance of multidisciplinary teams, enhancing symptom management, facilitating access to healthcare, and resulting in cost efficiency. For example, Solera Health, an American digital health company, entered into a partnership with Oshi Health, an American virtual gastrointestinal care company, as well as Vivante Health, another digital health company in the United States in March 2022. This step will lead to the availability of sophisticated digital therapy solutions that will facilitate the management and treatment of autoimmune gastrointestinal dysmotility. This alliance is targeted at enhancing patient's access to specialized care and improving the overall efficacy of treatments for individuals suffering from gastrointestinal disorders.

How Is the Autoimmune Gastrointestinal Dysmotility Market Segmented?
The autoimmune gastrointestinal dysmotility market covered in this report is segmented -

1) By Treatment Type: Medications, Surgical Interventions, Dietary Management, Physical Therapy
2) By Drug Class: Prokinetic Agents, Anti-Inflammatory Drugs, Immunosuppressive Drugs, Antibiotics
3) By Disease Type: Gastroparesis, Chronic Intestinal Pseudo-Obstruction (Cipo), Functional Dyspepsia, Irritable Bowel Syndrome (Ibs), Celiac Disease
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacies, Other Distribution Channels
5) By End User: Hospitals, Clinics, Home Care Settings, Research Institutions

Subsegments:
1) By Medications: Immunosuppressants, Corticosteroids, Prokinetic Agents, Antiemetics, Antispasmodics, Antibiotics
2) By Surgical Interventions: Gastrostomy, Jejunostomy, Colostomy, Ileostomy, Pyloroplasty, Colectomy
3) By Dietary Management: Enteral Nutrition, Parenteral Nutrition, Gluten-Free Diet, Elemental Diet, Small Frequent Meals
4) By Physical Therapy: Pelvic Floor Therapy, Abdominal Massage Therapy, Neuromuscular Electrical Stimulation (NMES), Biofeedback Therapy, Respiratory Muscle Training, Postural Training

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=24160&type=smp

Which Companies Are Leading the Charge in Autoimmune Gastrointestinal Dysmotility Market Innovation?
Major companies operating in the autoimmune gastrointestinal dysmotility market are AbbVie Inc., GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Chugai Pharmaceutical Co. Ltd., Zeria Pharmaceutical Co. Ltd., Ironwood Pharmaceuticals Inc., Vanda Pharmaceuticals Inc., Dr. Falk Pharma GmbH, Rose Pharma LLC, Parvus Therapeutics Inc., CinDome Pharma Inc., Neurogastrx Inc., Renexxion LLC, ISOThrive Inc., Ambrose Healthcare Inc., AnTolRx Inc., Enteralia Bioscience S.r.l., Immunic Inc., Mozart Therapeutics Inc.

Which Regions Are Leading the Global Autoimmune Gastrointestinal Dysmotility Market in Revenue?
North America was the largest region in the autoimmune gastrointestinal dysmotility market in 2024. The regions covered in the autoimmune gastrointestinal dysmotility market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=24160

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Speak With Our Expert:
Saumya Sahay,
Americas: +1 310-496-7795,
Asia: +44 7882 955267 & +91 8897263534,
Europe: +44 7882 955267,
Email: saumyas@tbrc.info

The Business Research Company - www.thebusinessresearchcompany.com

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.